title: The value of screening HIV-infected individuals for didanosine-related liver disease?
authors: Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK. andrew.scourfield@nhs.net
authors: Andrew
authors: A
authors: Scourfield
authors: Akil
authors: A
authors: Jackson
authors: Laura
authors: L
authors: Waters
authors: Brian
authors: B
authors: Gazzard
authors: Mark
authors: M
authors: Nelson
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D016049:Didanosine / Q000009:adverse effects*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000175:diagnosis* / Q000209:etiology*; D008403:Mass Screening
chemical_list: D019380:Anti-HIV Agents; D016049:Didanosine